REVIEW

The business of deubiquitination – location, location, location

[version 1; peer review: 2 approved]

Erin S. Coyne, Simon S. Wing

Polypeptide Laboratory, Departments of Medicine and Biochemistry, McGill University, McGill University Health Centre Research Institute, Montreal, QC, Canada

V1 First published: 11 Feb 2016, 5(F1000 Faculty Rev):163
<https://doi.org/10.12688/f1000research.7220.1>
 Latest published: 11 Feb 2016, 5(F1000 Faculty Rev):163
<https://doi.org/10.12688/f1000research.7220.1>

Abstract

A majority of proteins in the cell can be modified by ubiquitination, thereby altering their function or stability. This ubiquitination is controlled by both ubiquitinating and deubiquitinating enzymes (DUBs). The number of ubiquitin ligases exceeds that of DUBs by about eightfold, indicating that DUBs may have much broader substrate specificity. Despite this, DUBs have been shown to have quite specific physiological functions. This functional specificity is likely due to very precise regulation of activity arising from the sophisticated use of all mechanisms of enzyme regulation. In this commentary, we briefly review key features of DUBs with more emphasis on regulation. In particular, we focus on localization of the enzymes as a critical regulatory mechanism which when integrated with control of expression, substrate activation, allosteric regulation, and post-translational modifications results in precise spatial and temporal deubiquitination of proteins and therefore specific physiological functions. Identification of compounds that target the structural elements in DUBs that dictate localization may be a more promising approach to development of drugs with specificity of action than targeting the enzymatic activity, which for most DUBs is dependent on a thiol group that can react non-specifically with many compounds in large-scale screening.

Keywords

deubiquitination, deubiquitinating enzymes, DUB

Open Peer Review

Approval Status

	1	2
version 1 11 Feb 2016

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Henry L. Paulson**, University of Michigan, Ann Arbor, USA
 2. **Kazuhiro Iwai**, Kyoto University, Kyoto, Japan
- Any comments on the article can be found at the end of the article.

Corresponding author: Simon S. Wing (simon.wing@mcgill.ca)

Competing interests: The authors declare that they have no competing interests.

Grant information: Work in the authors' laboratory cited here was supported by grants from the Canadian Institutes of Health Research.

Copyright: © 2016 Coyne ES and Wing SS. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Coyne ES and Wing SS. **The business of deubiquitination – location, location, location [version 1; peer review: 2 approved]** F1000Research 2016, 5(F1000 Faculty Rev):163 <https://doi.org/10.12688/f1000research.7220.1>

First published: 11 Feb 2016, 5(F1000 Faculty Rev):163 <https://doi.org/10.12688/f1000research.7220.1>

Introduction

The conjugation of the 76 amino acid peptide ubiquitin to proteins is an important post-translational modification that can modulate most if not all cellular processes. This occurs via the consecutive action of three enzymes: E1 ubiquitin-activating enzymes (two mammalian genes), E2 ubiquitin conjugating enzymes (~35 genes), and E3 ubiquitin ligases (~750 genes)¹. The E3 ligases are critical for conferring substrate specificity (reviewed in 2). Ubiquitin is covalently linked by its C-terminal glycine to, most commonly, the ϵ -amino group of a lysine on a target protein through an isopeptide bond. Occasionally, ubiquitin can be conjugated to cysteine, serine, threonine, and N-terminal methionine residues^{3–7}. Subsequent ubiquitin moieties can be covalently linked to one of the seven lysine residues or the N-terminal methionine on the proximal ubiquitin to generate a polyubiquitin chain. Distinct functions are conferred depending on whether the protein is monoubiquitinated or polyubiquitinated and on the type of chain linkage. The two most common chain linkage types, K48 and K63, typically direct the substrate to different outcomes; the former is usually targeting proteins for degradation by the 26S proteasome, whereas the latter is generally involved in signal transduction, DNA repair, or endosomal sorting^{8–10}. Conjugation of a linear chain of ubiquitins linked via their N-terminal methionines can serve to recruit proteins in cytokine signaling^{11,12}. K11-linked chains¹³ and probably the remaining chain types¹⁴ can also target proteins to the proteasome. The 26S proteasome is a key mediator of intracellular protein homeostasis. It is an approximately 2.5-MDa macromolecular complex comprising a 20S cylindrical core particle capped at both ends by 19S regulatory particles. The 19S cap serves to recognize ubiquitinated substrates and allow their translocation into the lumen of the 20S core particle where the substrate then is hydrolyzed by the proteolytic machinery (reviewed in 2).

Importantly, ubiquitination is dynamic and reversible. Whereas early studies focused on understanding how ubiquitin is conjugated to substrates, recent years have seen markedly increased interest in deubiquitinating enzymes (DUBs). These studies have

demonstrated many functions for deubiquitination, giving support to the notion that DUBs play equally important roles as ligases do in controlling ubiquitination.

A number of excellent reviews on DUBs have been published recently^{15–18}. Therefore, in this commentary, we will highlight only the key concepts regarding the structure, functions, and mechanisms of these enzymes as these have been discussed in detail elsewhere. Instead, we will focus on the regulation of DUBs with emphasis on the role of localization in complexes and subcellular organelles in modulating their activities and function. We believe that such localization is a central factor in explaining how a relatively limited number of DUBs can exert a large range of specific functions. We will also comment briefly on the implications of this information on strategies for targeting DUBs for therapeutic purposes.

Structure and mechanism

DUBs are peptidases that catalyze the cleavage of the bond formed between ubiquitin and substrate or ubiquitin and ubiquitin. There are approximately 90 DUBs in the human genome, compared with the more than 750 E3 ligases¹. There are five DUB families classified on the basis of the homology of their catalytic domains. These families are the ubiquitin C-terminal hydrolase (UCH), ubiquitin-specific protease (USP), ovarian tumor domain (OTU), Machado-Joseph disease (MJD), and Jab1/Mpn/Mov34 (JAMM) enzymes (Table 1). All of these families are cysteine proteases, except for JAMM family members, which are metalloproteases. The crystal structures of members of each of these families have been solved (reviewed in 19). The catalytic mechanism of the cysteine protease DUBs is similar to that of plant papains, whereby cysteine, histidine, and aspartate residues form a catalytic triad where the histidine primes the cysteine for nucleophilic attack on the peptide bond and the aspartate aligns and polarizes the histidine. Metalloproteases require the co-ordination of a zinc ion for catalysis, which allows the abstraction of a hydrogen atom from a water molecule, generating a reactive hydroxyl ion capable of attacking the peptide bond.

Table 1. Families of deubiquitinating enzymes.

Family	Number	Deubiquitinating enzymes
Ubiquitin C-terminal hydrolase (UCH)	4	UCHL1 , UCHL3, UCHL5 , BAP1
Ubiquitin-specific protease (USP)	56	USP1 , USP2, USP3 , USP4 , USP5, USP6 , USP7 , USP8 , USP9X, USP9Y, USP10, USP11, USP12 , USP13, USP14 , USP15 , USP16 , USP18, USP19 , USP20 , USP21 , USP22 , USP24, USP25 , USP26 , USP27X, USP28 , USP29, USP30 , USP31, USP32, USP33 , USP34, USP35 , USP36 , USP37, USP38, USP39 , USP40, USP41, USP42 , USP43, USP44 , USP45, USP46, USP47, USP48, USP49, USP50, USP51, USP52, USP53, USP54, DUB3, CYLD , USPL1
Ovarian tumor (OTU)	16	OTUB1, OTUB2, OTUD1, OTUD3, OTUD4, OTUD5, OTUD6A, OTUD6B, OUT, YOD1, Otulin, A20 , Cezanne, Cezanne2, TRABID, ACPIP1
Machado-Joseph disease (MJD)	4	Ataxin-3, Ataxin-3-like, JosD1, JosD2
JAB1/MPN/Mov34 (JAMM)	11	PSMD7, PSMD14 , EIF3H, BRCC36 , CSCN5, CSCN6, AMSH , AMSH-LP, MPND, PRPF8, MYSM1

Enzymes cited in this commentary are shown in bold.

Function

Maintaining an adequate pool of free ubiquitin available for immediate conjugation is essential for the ability of the ubiquitin system to respond rapidly to changing cellular needs. DUBs play several critical roles in this general function of maintaining free ubiquitin. Ubiquitin is encoded in the human genome as four distinct genes: the two polyubiquitin genes *UBB* and *UBC* and the ubiquitin-fusion genes *UBA52* and *RPS27A*, which encode a single ubiquitin protein fused to the ribosomal proteins L40 and S27A, respectively. Thus, ubiquitin is synthesized *de novo* as fusion proteins that must be cleaved to generate free ubiquitin by DUBs. The free ubiquitin pool is also maintained by recycling ubiquitin that has been released from proteins just prior to destruction by either the proteasome or the endocytic, lysosomal pathway. DUBs act at both locations to provide this recycling function (see below). Finally, DUBs also contribute ubiquitin to the free pool through their removal of ubiquitin from specific substrates with the effect of reversing or preventing the effects of ubiquitination. DUBs can also act to edit or remodel ubiquitin chains on substrates²⁰ and thus may redirect their fate^{21,22}. The extent to which DUBs play such a remodeling role remains unknown. But the identification of DUBs which act on specific chain linkages—e.g. AMSH²³ and Ataxin3²⁰ for Lys 63-linked ubiquitin—clearly makes such a function plausible. Interestingly, DUBs can also inhibit conjugation by binding to the E2 and interfering with ubiquitin transfer to the E3^{24,25}.

Regulation

The many fewer DUBs compared with ubiquitin ligases suggest that DUBs may have much broader specificity with many more substrates per DUB than per ligase. Therefore, regulation of their activity is critical to maintain specificity and occurs through both intramolecular and external factors (reviewed in Sahtoe and Sixma¹⁸). Indeed, evidence to date indicates that DUBs employ all the classic mechanisms of enzyme regulation in sophisticated fashions.

Regulation of expression is well documented. Variation of expression of some enzymes in tissue(s)/cell type¹⁵ or upon specific stimuli²⁶ represents one layer of control which can allow DUBs to have specific effects. Such regulation of expression takes place through both transcriptional and post-transcriptional mechanisms, including regulation by miRNAs²⁷. Furthermore, regulation of enzyme levels by cleavage or degradation also occurs. USP1 cleaves itself following ultraviolet irradiation, leading to accumulation of the DNA replication processivity factor PCNA²⁸. The OTU domain containing A20 can be inactivated by cleavage by MALT1, a protein associated with mucosa-associated lymphoid tissue lymphoma²⁹. A number of DUBs exist in complex with E3s. The DUBs often can modulate ubiquitination of the E3^{30–32} as well as ubiquitination by the E3—whether of itself or other substrates (e.g. USP7 on p53³³ and its ligase Mdm2³⁴)—but the E3 can also modulate the stability of the DUB³⁵.

Substrate activation – The apo enzymes are often in an inactive state and this is due to being in a conformation that does not allow catalysis or due to auto-inhibitory loops that impair substrate access to the active site. Binding of the substrate³⁶ or the ubiquitin portion of the substrate³⁷ can result in reorganization of the enzyme into a

conformationally active form, indicating that substrate activation is an important regulatory mechanism.

Regulation by *post-translational modification* is also well described with examples of modulation of activity by phosphorylation^{38,39}, sumoylation⁴⁰, and ubiquitination^{41,42}. Furthermore, recent studies indicate that reactive oxygen species can inactivate many DUBs in a reversible manner by oxidizing the active-site cysteine to a cysteine sulphenic acid or sulphene amide^{43–45}.

Allosteric regulation due to binding of other proteins to the DUB is well described with examples of both activation^{46,47} and inhibition^{48,49} of enzyme activity.

Localization of the enzyme is becoming an increasingly appreciated regulatory mechanism allowing action on substrates that might not otherwise occur at significant rates if both enzyme and substrate were freely circulating, diluted in the cytoplasm. Here, we will highlight a few well-developed examples of localization – either to intracellular complexes or to organelles (Table 2) as a regulatory layer for DUB function. In many cases, the localization to a complex also results in allosteric regulation of the enzyme. A systematic study of localization of GFP-tagged DUBs indicates that approximately 25% of the enzymes are found in specific subcellular structures⁵⁰.

PMSD14, UCHL5, USP14, and the proteasome

The DUBs PMSD14/Rpn11, UCHL5/UCH37, and USP14 are all associated with the 19S regulatory cap of the proteasome; PMSD14 is a constituent component, whereas UCHL5 and USP14 are reversibly associated proteins. Upon binding to the 19S cap, UCHL5 and USP14 undergo restructuring, resulting in greatly increased enzymatic activity. Binding of UCHL5 to the proteasome repositions a crossover loop, thereby relieving an auto-inhibitory effect and allowing substrate access to the active site⁴⁸. Similarly, in USP14, the ubiquitin-binding pocket is obscured by two loops and binding to the 19S regulatory cap reveals the ubiquitin-binding site necessary for deubiquitination⁵¹. The localization of these DUBs gives them specific access to substrates associated with the proteasome. PMSD14 cleaves the ubiquitin chain at its junction with the substrate, thereby allowing efficient unwinding and insertion of the substrate into the 20S core and so its DUB activity promotes proteolysis. Both USP14 and UCHL5 have been shown to deubiquitinate and impair proteolysis of some substrates. However, it remains possible that, for some substrates, these enzymes may edit chains into forms which allow more effective binding to or processing by the proteasome.

AMSH and USP8 and ESCRT complexes

Receptor endocytosis followed by either recycling to the plasma membrane or trafficking through multi-vesicular bodies (MVBs) to lysosomes for degradation plays an important role in modulating signal transduction. During endocytosis, monoubiquitination and polyubiquitination of the receptor constitute a sorting signal that can be decoded by the ESCRT (endosomal sorting complex required for transport) complexes. The four ESCRT complexes (ESCRT-0, -I, -II, and -III) function together to generate MVBs by allowing the remodeling of the plasma membrane and the

Table 2. Subcellular localization of some deubiquitinating enzymes.

Cellular compartment	Family	Deubiquitinating enzymes	Reference
Nucleus	USP	USP1	81
		USP3	78
		USP4	82
		USP7	83
		USP16	77
		USP21	84
		USP22	85
		USP26	86
		USP28	87
		USP36	88
		USP39	89
		USP44	90
	UCH	UCHL5	91
		BAP1	92
Mitochondria	USP	USP8	65
		USP15	64
		USP15	
		USP30	61
		USP35	62
	USP	USP19	71
		USP20	94
		USP25	95
		USP33	94
	UCH	UCHL1	96
Endoplasmic reticulum	USP	USP32	97
		USP33	98
Golgi	USP	USP8	53
		AMSH	52

JAMM, JAB1/MPN/Mov34; MJD, Machado-Joseph disease; UCH, ubiquitin C-terminal hydrolase; USP, ubiquitin-specific protease.

budding and internalization of cargo-bearing vesicles. The contents of MVBs then are sent to the lysosome for degradation. Two DUBs are known to associate with ESCRT complexes in the endocytic/lysosomal pathway. AMSH (a JAMM family member with specificity for K63 chains) and USP8 associate with STAM proteins, a component of the ESCRT-0 complex^{52,53}. AMSH and USP8 can also interact with CHMP proteins that are components of the late ESCRT-III machinery^{23,54}. Association with ESCRT is necessary for AMSH function in endocytosis⁵⁵ and disruption of this association causes accumulation of the EGF receptor via impaired degradation⁵⁶. Thus, AMSH activity enhances receptor trafficking toward lysosomal degradation. USP8 can be both a positive and a negative regulator of receptor endocytosis. Loss of USP8 leads to

hyperubiquitination and enhanced degradation of EGF, MET, and ERBB3 receptors^{57,58} but increases the level of the Wnt receptor Frizzled by enhancing receptor recycling⁵⁹. The contrasting effects of loss of AMSH and USP8 on receptor stability as well as their differences in chain linkage specificity indicate that these ESCRT-associated DUBs have distinct functions.

USP30 and the mitochondria

Mitochondrial dysfunction can have profound effects on cell function and viability. Indeed, mitochondrial dysfunction and impaired clearance of damaged mitochondria are hallmarks of the neurodegenerative disorder Parkinson's disease. The ubiquitin ligase Parkin is mutated in an autosomal recessive form of the disease. In Parkin-mediated mitochondrial clearance (mitophagy), the kinase PINK1 accumulates on damaged mitochondria and recruits Parkin to ubiquitinate a variety of substrates on the mitochondria (reviewed in 60). USP30 was first identified as a DUB with a mitochondrial targeting sequence that is embedded in the mitochondrial outer membrane and plays a role in mitochondrial dynamics⁶¹. Subsequent studies revealed that it is a negative regulator of mitophagy. USP30 antagonizes Parkin-mediated mitophagy by deubiquitinating its target substrates⁶². It has also been shown to delay the recruitment of Parkin to damaged mitochondria⁶³. Other DUBs may also co-localize to the mitochondria and play a role in mitophagy. USP15 antagonizes Parkin mitochondrial ubiquitination⁶⁴, USP35 can delay Parkin-mediated mitophagy through unclear mechanisms⁶⁵, and USP8 removes K6-linked polyubiquitin chains from Parkin itself to facilitate its recruitment to damaged mitochondria⁶⁵. Additionally, ubiquitin itself can be phosphorylated on serine 65 by PINK1⁶⁶⁻⁶⁸. Interestingly, mitochondrial DUBs, including USP30, USP8, and USP15, are impaired at hydrolyzing these phosphoUb chains⁶⁹, thus providing an additional regulatory mechanism for Parkin-mediated mitophagy.

USP19 and the endoplasmic reticulum

USP19 was first identified as a DUB upregulated in skeletal muscle during catabolic conditions⁷⁰. It is expressed as two major isoforms: one cytoplasmic and the other with a transmembrane domain that results in anchoring of the C-terminal tail of the protein in the endoplasmic reticulum (ER) membrane with retention of the catalytic domain in the cytoplasm⁷¹. Overexpression of USP19 has been shown to rescue model substrates from ER-associated degradation (ERAD)⁷¹ as well as an ER-localized ligase MARCH6⁷². However, silencing of USP19 does not affect levels of ERAD substrates in a consistent manner^{72,73}, so its physiological functions at the ER remain unclear. USP19 can inhibit myogenic differentiation through suppression of an unfolded protein response that is required for muscle cell fusion⁷⁴. Interestingly, these effects are dependent on catalytic activity and occur with the ER but not the cytoplasmic isoform although both isoforms' catalytic domains are in the cytoplasm, indicating that the localization is critical for its ability to deubiquitinate specific substrates⁷⁴.

Chromatin deubiquitinating enzymes

Histone modifications are critical for DNA-dependent processes, including repair, replication, and transcription. Many DUBs have been shown to remove ubiquitin from chromatin, most commonly from histones H2A and H2B. MYSM1 and BRCC36 are two JAMM family members known to deubiquitinate H2A, with BRCC36

preferentially removing K63 polyubiquitin and suppressing DNA repair pathways. Importantly, MYSM1 and BRCC36 are associated with complexes that activate their deubiquitinating activity. MYSM1 is active as part of the 2A-DUB complex⁷⁵, whereas BRCC36 is associated with the BRCA1-A complex and this association activates its activity in the nucleus⁷⁶. Other DUBs capable of deubiquitinating histones include USP3, USP7, USP12, USP16, USP21, USP22, and USP44. Disruption of some of these DUBs results in altered cell cycle progression. Although USP3 and USP16 are not known to associate with any complexes, depletion of either enzyme results in aberrant cell cycle progression, with USP16 knockdown resulting in impaired mitosis⁷⁷ and depletion of USP3 resulting in a delay in S-phase progression⁷⁸. These different outcomes suggest that localization of DUBs to specific chromatin loci results in differential gene expression. DUBs could also target non-histone substrates at these sites to contribute to the phenotype.

Pharmacological targeting

Given the role of ubiquitination in many important processes that are deranged in disease, it is an attractive set of enzymes for pharmacological intervention. Targeting deubiquitination is also alluring in that the more limited number of DUBs in comparison with ligases makes phenotypic screens of DUBs more feasible. Indeed, the availability of small hairpin RNA (shRNA) or small interfering RNA (siRNA) libraries targeting all of the DUBs allows relatively rapid determination of whether loss of function of a DUB will yield a desirable phenotype. The limited number of DUBs allows screening to be applied to even relatively low-throughput assays.

Once loss of function of a DUB is shown to produce an effect that might be clinically desirable, the development of that observation into a potential drug is much more challenging. Although a number of assays of DUB activity are available and amenable to high-throughput screens of large compound libraries and have resulted in some lead compounds (reviewed in 79), these assays are at high risk of yielding many unproductive hits as almost all of the DUBs are thiol-based proteases and the highly reactive thiol group of the catalytic cysteine residue is well recognized to react non-specifically to many compounds. Inhibition of the enzymatic activity may not be desirable for other reasons. The large number of potential substrates for each DUB may lead to many more undesirable effects arising from inhibition of catalysis. Whole body gene inactivation of the enzyme in mice may be helpful in predicting the extent of such adverse effects.

A number of alternative strategies can be proposed to inhibit DUBs; however, these strategies require significantly more characterization of the enzymes. Since the enzymes must bind ubiquitin, an alternative approach to broad inhibition of a particular enzyme would be to inhibit its ability to bind ubiquitin. Generally, such inhibition would require knowledge of the structure of the enzyme bound to ubiquitin to identify the essential elements of the ubiquitin-binding domain(s). A recent mutagenic strategy has created ubiquitin variants that are able to bind and inhibit enzymatic activity⁸⁰. Remarkably, variants that were selective for specific DUBs were obtained. Crystallization of the ubiquitin variant/DUB complex identified specific residues on the DUB that contact the variant and that yield specificity for a particular enzyme. Some DUBs have multiple ubiquitin-binding sites that permit binding of ubiquitin chains.

These likely restrict the orientation of the ubiquitins in the chain that can be accommodated and therefore result in specificity of the enzyme for particular chain cleavages. Thus, inhibition of one of these specific domains may result in interference with ubiquitin chain binding or with the chain linkage specificity of the enzyme.

Targeting specific functions of a DUB may be achieved by identification of the specific substrates that mediate these effects. Subsequent structure function analyses then can identify the interacting domains of the enzyme and substrate and lead to the development of assays that can screen for compounds that interfere with the interaction. As discussed earlier, an important determining factor for both substrate specificity and regulation is the localization of the DUB. Once the mechanisms that result in targeting to a specific compartment or complex are determined, then assays that measure this binding can be similarly designed to screen for inhibitors. Since there are several examples in which complex formation or substrate binding activates the DUB, inhibitors that stabilize the enzyme in the auto-inhibited form could be developed. All of these approaches will rely heavily on structural studies both to help design the assay and to confirm that the identified compounds are functioning through the expected mechanisms.

Closing perspectives

Much progress has been made in our understanding of DUBs over the past 15 years. Structures have now been solved for many DUBs. However, in a number of cases, only the catalytic domain has been resolved and it is clear that important information resides in the other regions of the enzyme and will be needed to improve success in pharmacological targeting. A much larger gap in our understanding is in the functions of the enzymes, both at a molecular level (substrate identification) and at a cellular or whole organismal level (the physiological effects of removal of ubiquitin from the substrates). The former may be addressed through analysis of differential ubiquitination of proteins upon loss of function of the DUB. Although much progress has been made in ubiquitinome analysis, it remains to be determined whether current methods are sufficiently reproducible and precise to detect what might be small differences in steady-state levels of ubiquitination that arise upon DUB inactivation. The availability and application of methods for RNA silencing, gene editing, and gene knockout have been transformative in permitting the elucidation of physiological functions. However, such information remains available for only a small minority of the DUBs. Finally, our understanding of regulation of DUBs has progressed significantly. All of the classic types of enzyme regulation are present, but localization within organelles and complexes, allosteric regulation within complexes, and substrate activation appear to be prominent mechanisms which together allow tightly regulated activity on specific substrates. Identifying the structural elements underlying these mechanisms will offer the potential of targeting them to obtain drugs with highly specific effects.

Competing interests

The authors declare that they have no competing interests.

Grant information

Work in the authors' laboratory cited here was supported by grants from the Canadian Institutes of Health Research.

References

1. Hutchins AP, Liu S, Diez D, *et al.*: **The repertoires of ubiquitinating and deubiquitinating enzymes in eukaryotic genomes.** *Mol Biol Evol.* 2013; **30**(5): 1172–87.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Glickman MH, Ciechanover A: **The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction.** *Physiol Rev.* 2002; **82**(2): 373–428.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. **F** Cadwell K, Coscoy L: **Ubiquitination on nonlysine residues by a viral E3 ubiquitin ligase.** *Science.* 2005; **309**(5731): 127–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
4. Ciechanover A, Ben-Saadon R: **N-terminal ubiquitination: more protein substrates join in.** *Trends Cell Biol.* 2004; **14**(3): 103–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Tait SW, de Vries E, Maas C, *et al.*: **Apoptosis induction by Bid requires unconventional ubiquitination and degradation of its N-terminal fragment.** *J Cell Biol.* 2007; **179**(7): 1453–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. McDowell GS, Kucerova R, Philpott A: **Non-canonical ubiquitylation of the proneural protein Ngn2 occurs in both *Xenopus* embryos and mammalian cells.** *Biochem Biophys Res Commun.* 2010; **400**(4): 655–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Vosper JM, McDowell GS, Hindley CJ, *et al.*: **Ubiquitylation on canonical and non-canonical sites targets the transcription factor neurogenin for ubiquitin-mediated proteolysis.** *J Biol Chem.* 2009; **284**(23): 15458–68.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Haglund K, Dikic I: **Ubiquitylation and cell signaling.** *EMBO J.* 2005; **24**(19): 3353–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Panier S, Durocher D: **Regulatory ubiquitylation in response to DNA double-strand breaks.** *DNA Repair (Amst).* 2009; **8**(4): 436–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Clague MJ, Urbé S: **Endocytosis: the DUB version.** *Trends Cell Biol.* 2006; **16**(11): 551–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Iwai K, Fujita H, Sasaki Y: **Linear ubiquitin chains: NF- κ B signalling, cell death and beyond.** *Nat Rev Mol Cell Biol.* 2014; **15**(8): 503–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. **F** Tokunaga F, Sakata S, Saeki Y, *et al.*: **Involvement of linear polyubiquitylation of NEMO in NF- κ B activation.** *Nat Cell Biol.* 2009; **11**(2): 123–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
13. Jin L, Williamson A, Banerjee S, *et al.*: **Mechanism of ubiquitin-chain formation by the human anaphase-promoting complex.** *Cell.* 2008; **133**(4): 653–65.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. **F** Xu P, Duong DM, Seyfried NT, *et al.*: **Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation.** *Cell.* 2009; **137**(1): 133–45.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
15. Clague MJ, Barsukov I, Coulson JM, *et al.*: **Deubiquitylases from genes to organism.** *Physiol Rev.* 2013; **93**(3): 1289–315.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Eletre ZM, Wilkinson KD: **Regulation of proteolysis by human deubiquitinating enzymes.** *Biochim Biophys Acta.* 2014; **1843**(1): 114–28.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Wolberger C: **Mechanisms for regulating deubiquitinating enzymes.** *Protein Sci.* 2014; **23**(4): 344–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Sahtoe DD, Sixma TK: **Layers of DUB regulation.** *Trends Biochem Sci.* 2015; **40**(8): 456–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Komander D, Clague MJ, Urbé S: **Breaking the chains: structure and function of the deubiquitinases.** *Nat Rev Mol Cell Biol.* 2009; **10**(8): 550–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Winborn BJ, Travis SM, Todi SV, *et al.*: **The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys⁶³ linkages in mixed linkage ubiquitin chains.** *J Biol Chem.* 2008; **283**(39): 26436–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. **F** Wertz IE, O'Rourke KM, Zhou H, *et al.*: **De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF- κ B signalling.** *Nature.* 2004; **430**(7000): 694–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
22. **F** Newton K, Matsumoto ML, Wertz IE, *et al.*: **Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies.** *Cell.* 2008; **134**(4): 668–78.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
23. **F** McCullough J, Row PE, Lorenzo O, *et al.*: **Activation of the endosome-associated ubiquitin isopeptidase AMSH by STAM, a component of the multivesicular body-sorting machinery.** *Curr Biol.* 2006; **16**(2): 160–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
24. Durcan TM, Kontogianni M, Bedard N, *et al.*: **Ataxin-3 deubiquitination is coupled to Parkin ubiquitination via E2 ubiquitin-conjugating enzyme.** *J Biol Chem.* 2012; **287**(1): 531–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. **F** Nakada S, Tai I, Panier S, *et al.*: **Non-canonical inhibition of DNA damage-dependent ubiquitination by OTUB1.** *Nature.* 2010; **466**(7309): 941–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
26. Zhu Y, Lambert K, Corless C, *et al.*: **DUB-2 is a member of a novel family of cytokine-inducible deubiquitinating enzymes.** *J Biol Chem.* 1997; **272**(1): 51–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. **F** Wu N, Zhang C, Bai C, *et al.*: **MIR-4782-3p inhibited non-small cell lung cancer growth via USP14.** *Cell Physiol Biochem.* 2014; **33**(2): 457–67.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
28. Huang TT, Nijman SM, Mirchandani KD, *et al.*: **Regulation of monoubiquitinated PCNA by DUB autocleavage.** *Nat Cell Biol.* 2006; **8**(4): 339–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Coornaert B, Baens M, Heyninck K, *et al.*: **T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF- κ B inhibitor A20.** *Nat Immunol.* 2008; **9**(3): 263–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Mouchantaf R, Azakir BA, McPherson PS, *et al.*: **The ubiquitin ligase itch is auto-ubiquitylated *in vivo* and *in vitro* but is protected from degradation by interacting with the deubiquitylating enzyme FAM/USP9X.** *J Biol Chem.* 2006; **281**(50): 38738–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Wu X, Yen L, Irwin L, *et al.*: **Stabilization of the E3 ubiquitin ligase Nrdp1 by the deubiquitinating enzyme USP8.** *Mol Cell Biol.* 2004; **24**(17): 7748–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Lu Y, Adegoke OA, Nepveu A, *et al.*: **USP19 deubiquitinating enzyme supports cell proliferation by stabilizing KPC1, a ubiquitin ligase for p27^{Kip1}.** *Mol Cell Biol.* 2009; **29**(2): 547–58.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. **F** Li M, Chen D, Shiloh A, *et al.*: **Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization.** *Nature.* 2002; **416**(6881): 648–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
34. Li M, Brooks CL, Kon N, *et al.*: **A dynamic role of HAUSP in the p53-Mdm2 pathway.** *Mol Cell.* 2004; **13**(6): 879–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. **F** Velasco K, Zhao B, Callegari S, *et al.*: **An N-terminal SIAH-interacting motif regulates the stability of the ubiquitin specific protease (USP)-19.** *Biochem Biophys Res Commun.* 2013; **433**(4): 390–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
36. **F** Lingaraju GM, Bunker RD, Cavadini S, *et al.*: **Crystal structure of the human COP9 signalosome.** *Nature.* 2014; **512**(7513): 161–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
37. **F** Hu M, Li P, Li M, *et al.*: **Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde.** *Cell.* 2002; **111**(7): 1041–54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
38. Hutt J, Turk BE, Asara JM, *et al.*: **I κ B kinase beta phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF- κ B pathway.** *Mol Cell Biol.* 2007; **27**(21): 7451–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. **F** Edelmann MJ, Kramer HB, Altun M, *et al.*: **Post-translational modification of the deubiquitinating enzyme Otubain 1 modulates active RhoA levels and susceptibility to *Yersinia* invasion.** *FEBS J.* 2010; **277**(11): 2515–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
40. Meulmeester E, Kunze M, Hsiao HH, *et al.*: **Mechanism and consequences for paralog-specific sumoylation of ubiquitin-specific protease 25.** *Mol Cell.* 2008; **30**(5): 610–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Fernández-Montalván A, Bouwmeester T, Joberty G, *et al.*: **Biochemical characterization of USP7 reveals post-translational modification sites and structural requirements for substrate processing and subcellular localization.** *FEBS J.* 2007; **274**(16): 4256–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Todi SV, Winborn BJ, Scaglione KM, *et al.*: **Ubiquitination directly enhances activity of the deubiquitinating enzyme ataxin-3.** *EMBO J.* 2009; **28**(4): 372–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. **F** Kulathu Y, Garcia FJ, Mevissen TE, *et al.*: **Regulation of A20 and other OTU deubiquitinases by reversible oxidation.** *Nat Commun.* 2013; **4**: 1569.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
44. **F** Cotto-Rios XM, Békés M, Chapman J, *et al.*: **Deubiquitinases as a signaling target of oxidative stress.** *Cell Rep.* 2012; **2**(6): 1475–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
45. **F** Lee J, Baek K, Soetandyo N, *et al.*: **Reversible inactivation of deubiquitinases by reactive oxygen species *in vitro* and in cells.** *Nat Commun.* 2013; **4**: 1568.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

46. **F** Faesen AC, Dirac AM, Shanmugham A, *et al.*: Mechanism of USP7/HAUSP activation by its C-terminal ubiquitin-like domain and allosteric regulation by GMP-synthetase. *Mol Cell*. 2011; 44(1): 147–59.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
47. **F** Cohn MA, Kowal P, Yang K, *et al.*: A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway. *Mol Cell*. 2007; 28(5): 786–97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
48. **F** Sahtoe DD, van Dijk WJ, El Oualid F, *et al.*: Mechanism of UCH-L5 activation and inhibition by DEUBAD domains in RPN13 and INO80G. *Mol Cell*. 2015; 57(5): 887–900.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
49. **F** VanderLinden RT, Hemmis CW, Schmitt B, *et al.*: Structural basis for the activation and inhibition of the UCH37 deubiquitylase. *Mol Cell*. 2015; 57(5): 901–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
50. **F** Urbé S, Liu H, Hayes SD, *et al.*: Systematic survey of deubiquitinase localization identifies USP21 as a regulator of centrosome- and microtubule-associated functions. *Mol Biol Cell*. 2012; 23(6): 1095–103.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
51. **F** Hu M, Li P, Song L, *et al.*: Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14. *EMBO J*. 2005; 24(21): 3747–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
52. **F** Tanaka N, Kaneko K, Asao H, *et al.*: Possible involvement of a novel STAM-associated molecule “AMSH” in intracellular signal transduction mediated by cytokines. *J Biol Chem*. 1999; 274(27): 19129–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
53. **F** Kato M, Miyazawa K, Kitamura N: A deubiquitinating enzyme UBPY interacts with the Src homology 3 domain of Hrs-binding protein via a novel binding motif PX(V/I)(D/N)RXKPK. *J Biol Chem*. 2000; 275(48): 37481–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
54. **F** Row PE, Liu H, Hayes S, *et al.*: The MIT domain of UBPY constitutes a CHMP binding and endosomal localization signal required for efficient epidermal growth factor receptor degradation. *J Biol Chem*. 2007; 282(42): 30929–37.
[PubMed Abstract](#) | [Publisher Full Text](#)
55. **F** Sierra MI, Wright MH, Nash PD: AMSH interacts with ESCRT-0 to regulate the stability and trafficking of CXCR4. *J Biol Chem*. 2010; 285(18): 13990–4004.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
56. **F** Ma YM, Boucrot E, Villén J, *et al.*: Targeting of AMSH to endosomes is required for epidermal growth factor receptor degradation. *J Biol Chem*. 2007; 282(13): 9805–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
57. **F** Niendorf S, Oksche A, Kisser A, *et al.*: Essential role of ubiquitin-specific protease 8 for receptor tyrosine kinase stability and endocytic trafficking in vivo. *Mol Cell Biol*. 2007; 27(13): 5029–39.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
58. **F** Berlin I, Schwartz H, Nash PD: Regulation of epidermal growth factor receptor ubiquitination and trafficking by the USP8-STAM complex. *J Biol Chem*. 2010; 285(45): 34909–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
59. **F** Mukai A, Yamamoto-Hino M, Awano W, *et al.*: Balanced ubiquitylation and deubiquitylation of Frizzled regulate cellular responsiveness to Wg/Wnt. *EMBO J*. 2010; 29(13): 2114–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
60. **F** Durcan TM, Fon EA: The three ‘P’s of mitophagy: PARKIN, PINK1, and post-translational modifications. *Genes Dev*. 2015; 29(10): 989–99.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
61. **F** Nakamura N, Hirose S: Regulation of mitochondrial morphology by USP30, a deubiquitinating enzyme present in the mitochondrial outer membrane. *Mol Biol Cell*. 2008; 19(5): 1903–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
62. **F** Bingol B, Tea JS, Phu L, *et al.*: The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. *Nature*. 2014; 510(7505): 370–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
63. **F** Wang Y, Serricchio M, Jauregui M, *et al.*: Deubiquitinating enzymes regulate PARK2-mediated mitophagy. *Autophagy*. 2015; 11(4): 595–606.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
64. **F** Cornelissen T, Haddad D, Wauters F, *et al.*: The deubiquitinase USP15 antagonizes Parkin-mediated mitochondrial ubiquitination and mitophagy. *Hum Mol Genet*. 2014; 23(19): 5227–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
65. **F** Durcan TM, Tang MY, Péresse JR, *et al.*: USP8 regulates mitophagy by removing K6-linked ubiquitin conjugates from parkin. *EMBO J*. 2014; 33(21): 2473–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
66. **F** Kane LA, Lazarou M, Fogel AI, *et al.*: PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. *J Cell Biol*. 2014; 205(2): 143–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
67. **F** Kazlauskaitė A, Kondapalli C, Gourlay R, *et al.*: Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser⁶⁵. *Biochem J*. 2014; 460(1): 127–39.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
68. **F** Koyano F, Okatsu K, Kosako H, *et al.*: Ubiquitin is phosphorylated by PINK1 to activate parkin. *Nature*. 2014; 510(7503): 162–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
69. **F** Wauer T, Swatek KN, Wagstaff JL, *et al.*: Ubiquitin Ser65 phosphorylation affects ubiquitin structure, chain assembly and hydrolysis. *EMBO J*. 2015; 34(3): 307–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
70. **F** Combaret L, Adegoke OA, Bedard N, *et al.*: USP19 is a ubiquitin-specific protease regulated in rat skeletal muscle during catabolic states. *Am J Physiol Endocrinol Metab*. 2005; 288(4): E693–700.
[PubMed Abstract](#) | [Publisher Full Text](#)
71. **F** Hassink GC, Zhao B, Sompallae R, *et al.*: The ER-resident ubiquitin-specific protease 19 participates in the UPR and rescues ERAD substrates. *EMBO Rep*. 2009; 10(7): 755–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
72. **F** Nakamura N, Harada K, Kato M, *et al.*: Ubiquitin-specific protease 19 regulates the stability of the E3 ubiquitin ligase MARCH6. *Exp Cell Res*. 2014; 328(1): 207–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
73. **F** Lee JG, Kim W, Gygi S, *et al.*: Characterization of the deubiquitinating activity of USP19 and its role in endoplasmic reticulum-associated degradation. *J Biol Chem*. 2014; 289(6): 3510–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
74. **F** Wiles B, Miao M, Coyne E, *et al.*: USP19 deubiquitinating enzyme inhibits muscle cell differentiation by suppressing unfolded-protein response signaling. *Mol Biol Cell*. 2015; 26(5): 913–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
75. **F** Zhu P, Zhou W, Wang J, *et al.*: A histone H2A deubiquitinase complex coordinating histone acetylation and H1 dissociation in transcriptional regulation. *Mol Cell*. 2007; 27(4): 609–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
76. **F** Feng L, Wang J, Chen J: The Lys⁶³-specific deubiquitinating enzyme BRCC36 is regulated by two scaffold proteins localizing in different subcellular compartments. *J Biol Chem*. 2010; 285(40): 30982–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
77. **F** Joo HY, Zhai L, Yang C, *et al.*: Regulation of cell cycle progression and gene expression by H2A deubiquitination. *Nature*. 2007; 449(7165): 1068–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
78. **F** Nicassio F, Corrado N, Vissers JH, *et al.*: Human USP3 is a chromatin modifier required for S phase progression and genome stability. *Curr Biol*. 2007; 17(22): 1972–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
79. **F** Ndubaku C, Tsui V: Inhibiting the deubiquitinating enzymes (DUBs). *J Med Chem*. 2015; 58(4): 1581–95.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
80. **F** Ernst A, Avvakumov G, Tong J, *et al.*: A strategy for modulation of enzymes in the ubiquitin system. *Science*. 2013; 339(6119): 590–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
81. **F** Nijman SM, Huang TT, Dirac AM, *et al.*: The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. *Mol Cell*. 2005; 17(3): 331–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
82. **F** Song EJ, Werner SL, Neubauer J, *et al.*: The Prp19 complex and the Usp4^{Sant3} deubiquitinating enzyme control reversible ubiquitination at the spliceosome. *Genes Dev*. 2010; 24(13): 1434–47.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
83. **F** van Loosdregt J, Fieskens V, Fu J, *et al.*: Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. *Immunity*. 2013; 39(2): 259–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
84. **F** García-Santesteban I, Bañuelos S, Rodríguez JA: A global survey of CRM1-dependent nuclear export sequences in the human deubiquitinase family. *Biochem J*. 2012; 441(1): 209–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
85. **F** Xiong J, Wang Y, Gong Z, *et al.*: Identification of a functional nuclear localization signal within the human USP22 protein. *Biochem Biophys Res Commun*. 2014; 449(1): 14–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
86. **F** Dirac AM, Bernards R: The deubiquitinating enzyme USP26 is a regulator of androgen receptor signaling. *Mol Cancer Res*. 2010; 8(6): 844–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
87. **F** Popov N, Wanzel M, Madiredjo M, *et al.*: The ubiquitin-specific protease USP28 is required for MYC stability. *Nat Cell Biol*. 2007; 9(7): 765–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
88. **F** Sun XX, He X, Yin L, *et al.*: The nucleolar ubiquitin-specific protease USP36 deubiquitinates and stabilizes c-Myc. *Proc Natl Acad Sci U S A*. 2015; 112(12): 3734–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
89. **F** Makarova OV, Makarov EM, Lührmann R: The 65 and 110 kDa SR-related proteins of the U4/U6.5 tri-snRNP are essential for the assembly of mature spliceosomes. *EMBO J*. 2001; 20(10): 2553–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

90. Suresh B, Ramakrishna S, Lee HJ, *et al.*: **K48- and K63-linked polyubiquitination of deubiquitinating enzyme USP44.** *Cell Biol Int.* 2010; **34**(8): 799–808.
[PubMed Abstract](#) | [Publisher Full Text](#)
91. Yao T, Song L, Jin J, *et al.*: **Distinct modes of regulation of the Uch37 deubiquitinating enzyme in the proteasome and in the Ino80 chromatin-remodeling complex.** *Mol Cell.* 2008; **31**(6): 909–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
92. Mashtalir N, Daou S, Barbour H, *et al.*: **Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O.** *Mol Cell.* 2014; **54**(3): 392–406.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
93. Tait D, Riccio M, Sittler A, *et al.*: **Ataxin-3 is transported into the nucleus and associates with the nuclear matrix.** *Hum Mol Genet.* 1998; **7**(6): 991–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
94. Curcio-Morelli C, Zavacki AM, Christofollete M, *et al.*: **Deubiquitination of type 2 iodothyronine deiodinase by von Hippel-Lindau protein-interacting deubiquitinating enzymes regulates thyroid hormone activation.** *J Clin Invest.* 2003; **112**(2): 189–96.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
95. Blount JR, Burr AA, Denuc A, *et al.*: **Ubiquitin-specific protease 25 functions in Endoplasmic Reticulum-associated degradation.** *PLoS One.* 2012; **7**(5): e36542.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
96. Liu Z, Meray RK, Grammatopoulos TN, *et al.*: **Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease.** *Proc Natl Acad Sci U S A.* 2009; **106**(12): 4635–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
97. Akhavantabasi S, Akman HB, Sapmaz A, *et al.*: **USP32 is an active, membrane-bound ubiquitin protease overexpressed in breast cancers.** *Mamm Genome.* 2010; **21**(7–8): 388–97.
[PubMed Abstract](#) | [Publisher Full Text](#)
98. Thorne C, Eccles RL, Coulson JM, *et al.*: **Isoform-specific localization of the deubiquitinase USP33 to the Golgi apparatus.** *Traffic.* 2011; **12**(11): 1563–74.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Kazuhiro Iwai**

Department of Molecular and Cellular Physiology, Kyoto University, Kyoto, Japan

Competing Interests: No competing interests were disclosed.

2. **Henry L. Paulson**

Department of Neurology, University of Michigan, Ann Arbor, MI, USA

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research